H. Ford

发表

Combination of raltitrexed with other cytotoxic agents: rationale and preclinical observations.

A. Jackman, R. Kimbell, H. Ford, 1999, European journal of cancer.

Phase I study of irinotecan and raltitrexed in patients with advanced astrointestinal tract adenocarcinoma

D. Cunningham, G. Aherne, P. Ross, 2000, British Journal of Cancer.

Protracted venous infusion 5-fluorouracil and interferon-alpha in advanced and refractory colorectal cancer.

A. Norman, M. Nicolson, D. Cunningham, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer.

A. Norman, D. Tait, Gina Brown, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

TS Inhibitors and Antifolates

D. Cunningham, H. Ford, 2002 .

Gefitinib for oesophageal cancer: a cog in need of a wheel?

H. Ford, 2014, The Lancet. Oncology.

Improved long‐term survival after resection of colorectal liver metastases following staging with FDG positron emission tomography

Charles B. Wilson, A. Jah, U. Sadat, 2014, Journal of surgical oncology.

Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma

E. Godfrey, M. O’Donovan, R. Fitzgerald, 2015, British Journal of Cancer.

51 The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer: analysis from a prospective randomised controlled trial

A. Norman, D. Tait, D. Cunningham, 2003 .

COUGAR-02: A randomized phase III study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinoma.

D. Cunningham, J. Bridgewater, S. Madhusudan, 2013 .

Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331.

I. Judson, D. Cunningham, A. Jackman, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Safety of raltitrexed

D. Cunningham, H. Ford, 1999, The Lancet.

Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed.

David Cunningham, D. Cunningham, K. Danenberg, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

The role of multi-disciplinary teams in decision-making for patients with recurrent malignant disease

J. Blazeby, T. Crosby, C. Reid, 2012, Palliative medicine.

Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance

Simon Tavaré, Achilleas Achilleos, Andy G. Lynch, 2016, Nature Genetics.

A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer.

T. Hickish, J. Cassidy, I. Macpherson, 2014, European journal of cancer.

Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis

Rebecca C Fitzgerald, Carlos Caldas, Arusha Oloumi, 2014, Nature Genetics.

A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF).

T. Hickish, A. Norman, M. Nicolson, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study.

F. Cappuzzo, F. Hirsch, E. Duffield, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Docetaxel and its potential in the treatment of refractory esophagogastric adenocarcinoma

I. Gounaris, H. Ford, 2015, Therapeutic advances in gastroenterology.

Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1

S. Tavaré, P. Edwards, H. Barr, 2015, Scientific Reports.

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.

D. Cunningham, J. Bridgewater, S. Madhusudan, 2014, The Lancet. Oncology.

The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma.

T. Eisen, I. Smith, P. Ross, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data

S. Park, A. Marshall, J. Dunn, 2016, British Journal of Cancer.

The Cost Effectiveness of Docetaxel and Active Symptom Control versus Active Symptom Control Alone for Refractory Oesophagogastric Adenocarcinoma: Economic Analysis of the COUGAR-02 Trial

A. Marshall, J. Dunn, C. Hulme, 2015, PharmacoEconomics.

B3-04: Gefitinib (IRESSA) versus vinorelbine in chemonaïve elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized Phase II study

F. Hirsch, E. Duffield, A. Armour, 2007 .

Cougar-02 : a randomized phase III study of docetaxel versus active symptom control in patients with relapsed esophago-gastric adenocarcinoma

D. Cunningham, J. Bridgewater, S. Madhusudan, 2013 .

Author Correction: Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1

S. Tavaré, A. Hindmarsh, V. Sujendran, 2019, Scientific Reports.

Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma.

T. Hickish, A. Norman, D. Tait, 2004, Clinical colorectal cancer.

A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer

A. Makris, D. Miles, S. Johnston, 2006, Cancer Chemotherapy and Pharmacology.

Docetaxel and its potential in the treatment of refractory esophagogastric adenocarcinoma

I. Gounaris, H. Ford, 2015, Therapeutic advances in gastroenterology.

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.

D. Cunningham, J. Bridgewater, S. Madhusudan, 2014, The Lancet. Oncology.